Leukemia Research
Volume 24, Issue 12 , Pages 1009-1011 , December 2000

Amifostine: a tonic or toxin to myeloid progenitors

Received 16 June 2000 ,Accepted 16 June 2000.

References 

  1. List AF, Heaton R, Glinsmann-Gibson B, Capizzi RL. Amifostine stimulates the formation of multipotent and erythroid hematopoietic progenitors. Leukemia. 1998;12(10):1596
  2. Smoluk GD, Fahey RC, Calabro-Jones PM, Aguilera JA, Ward JF. Radioprotection of cells in culture by WR-2721 and derivatives: form of the drug responsible for protection. Cancer Res. 1988;48:3641
  3. Shaw LM, Turrisi AT, Glover DJ, Bonner HS, Norfleet AL, Weiler C. Human pharmacokinetics of WR-2721. Int. J. Rad. Oncol. Biol. Phys. 1986;12:1501
  4. Calabro-Jones PM, Aguilera JA, Ward JF, Smoluk GD, Fahey RC. Uptake of WR-2721 derivatives by cells in culture: identification of the transported form of the drug. Cancer Res. 1988;48:3634
  5. Wasserman TH, Phillips TL, Ross G, Kane LJ. Differential protection against cytotoxic chemotherapeutic effects on bone marrow CFUs by Wr-2721. Cancer Clin. Trials. 1981;4:3
  6. Valeriote F, Tolen S. Protection and potentiation of nitrogen mustard cytotoxicity by WR-2721. Cancer Res. 1982;42:4330
  7. Shpall EJ, Stemmer SM, Hami L. Amifostine (WR-2721) shortens the engraftment period of 4-hydroperoxycyclophosphamide-purged bone marrow in breast cancer patients receiving high-dose chemotherapy with autologous bone marrow support. Blood. 1994;83:3132
  8. List AF, Heaton R, Glinsmann-Gibson B, Capizzi R. Amifostine protects primitive hematopoietic progenitors against chemotherapy cytotoxicity. Semin. Oncol. 1996;23(8):58
  9. List AF. Use of amifostine in hematologic malignancies in hematologic malignancies, myelodysplastic syndromes and acute leukemia. Semin. Oncol. 1999;26(Suppl 7):61
  10. List AF. Hematopoietic stimulation by amifostine and sodium phenylbutyrate: what is the potential in MDS?. Leuk. Res. 1998;22:S7
  11. Mitchell JL, Judd GG, Diveley RR, Choe CY, Leyser A. Involvement of the polyamine transport system in cellular uptake of the radioprotectants WR-1065 and WR-33278. Carcinogenesis. 1995;16(12):3063
  12. Wyatt I, Moore RB, Smith LL. Competition for polyamine uptake into rat lung slices by WR-2721 and analogues. Int. J. Rad. Biol. 1989;55:463
  13. Saverio B, Pierpaola D, Serenella A, Cesare C, Bruno M, Auro T, et al. Tumor progression is accompanied by significant changes in the levels of expression of polyamine metabolism regulatory genes and clusterin (sulfated glycoprotein 2) in human prostate cancer specimens. Cancer Res. 2000;60:28
  14. Flamigni F, Facchini A, Capanni C, Stefanelli C, Tantini B, Calderera CM. p44/42 mitogen-activated protein kinase is involved in the expression of ornithine decarboxylase in leukemia L1210 cells. Biochem. J. 1999;341:363
  15. Newton GL, Aguilera JA, Ward FJ, Fahey RC. Binding of radioprotective thiols and disulfides in Chinese hamster V79 cell nuclei. Rad. Res. 1996;146:298
  16. Meier T, Issels RD. Degradation of 2-(3-aminopropylamino)-ethanethiol (WR-1065) by Cu-dependent amine oxidases and influence of glutathione status of Chinese hamster ovary cells. Biochem. Pharm. 1995;50:489
  17. Shirihai OS, Gregory T, Yu C, Orkin SH, Weiss MJ. ABC-me: a novel mitochondrial transporter induced by GATA-1 during erythroid differentiation. EMBO J. 2000;19:2492
  18. North S, El-Ghissassi F, Pluquet O, Verhaegh G, Hainaut P. The cytoprotective aminothiol WR1065 activates p21 waf-1 and down regulates cell cycle progression through a p53-dependent pathway. Oncogene. 2000;19:1206
  19. Grdina DJ, Constantinou A, Shigematsu N, Murley JS. Inhibition of topoisomerase II alpha activity in CHO K1 cells by 2-[(aminopropyl)amino]ethanethiol (WR-1065). Rad. Res. 1994;138:44
  20. Sigdestad CP, Bergquist BL, Grdina DJ. The effect of chemical radiation protectors on cell cycle progression after gamma or neutron irradiation. Cell Proliferation. 1991;24:71
  21. Grdina DJ, Sigdestad CP. Chemical protection and cell-cycle effects on radiation-induced mutagenesis. Cell Proliferation. 1992;25:23
  22. Ushmorov A, Hack V, Droge W. Differential reconstitution of mitochondrial respiratory chain activity and plasma redox state by cysteine and ornithine in a model of cancer cachexia. Cancer Res. 1999;59:3527
  23. Ha HC, Yager JD, Woster PA, Casero RA. Structural specificity of polyamines and polyamine analogues in the protection of DNA from strand breaks induced by reactive oxygen species. Biochem. Biophys. Res. Commun. 1998;244:298
  24. Ha HC, Sirisoma NS, Kuppusamy P, Zweier JL, Woster PM, Casero RA. The natural polyamine spermine functions directly as a free radical scavenger. Proc. Natl. Acad. Sci. USA. 1998;95:11140
  25. Quinones HI, Marek S, Berner WE. The antizyme-dependent polyamine transporter mediates radioprotection by the amifostine derivative WR-1065. Proc. Am. Assoc. Cancer Res. 1999;40:518a
  26. Matsufuji S, Matsufuji T, Miyazaki Y, Murakami Y, Atkins JF, Gesteland RF, et al. Autoregulatory frameshifting in decoding mammalian ornithine decarboxylase antizyme. Cell. 1995;80:51
  27. Murakami Y, Matsufuji S, Miyazaki Y, Hayashi S. Destabilization of ornithine decarboxylase by transfected antizyme gene expression in hepatoma tissue culture cells. J. Biol. Chem. 1992;267:13138
  28. Romano MF, Lamberti A, Bisogni R, et al.  Amifostine inhibits hematopoietic progenitor cell apoptosis by activating NF-κB/Rel transcription factors. Blood. 1999;94:4060
  29. List AF, Heaton R, Glinsmann-Gibson B, Capizzi R. Amifostine stimulates formation of multipotent progenitors and generates macroscopic colonies in normal and myelodysplastic bone marrow. ASCO Proceed. 1999;15:449a
  30. Klimecki W, Heaton R, Glinsmann-Gibson B, List A. Amifostine suppresses apoptosis in myelodysplastic CD34+ cells and promotes progenitor growth via polyamine-like effects. Blood. 1997;80(Suppl 1):520a
  31. Ribizzi I, Darnowski JW, Goulette FA, Sertoli MR, Calabresi P. Amifostine cytotoxicity and induction of apoptosis in a human myelodysplastic cell line. Leuk. Res. 2000;24:519
  32. Douay L, Hu C, Giarratana MC, Bouchet S, Conlon J, Capizzi RL, et al. Amifostine improves the antileukemic therapeutic index of mafosfamide: implications for bone marrow purging. Blood. 1995;86:2849
  33. Valeriote F, Tolen S. Protection and potentiation of nitrogen mustard cytotoxicity by WR-2721. Cancer Res. 1982;42:4330
  34. Huang XK, Gao XZ, Burke P, Raza A, Preisler HD. The effects of amifostine on the clonogenic proliferation in vitro of myelodysplastic and acute and chronic myelogenous leukemia cells. ASCO Proceed. 1997;16:1848a
  35. List AF, Holmes H, Greenberg PL, Bennett JM, Oster W. Phase II study of amifostine in patients with myelodysplastic syndrome (MDS). Blood. 1999;94 (10) Suppl. 1:305a
  36. Preisler H, Venugopal P, Galvez A. Effective treatment of poor prognosis AML. Blood. 1997;80:2257a
  37. Flomenberg N, Garcia-Manero G, Grosso D, et al.  High CR rate and normal organ cytoprotection using dose escalation of idarubicin with amifostine in high risk patients with AML. ASCO Proceed. 2000;19:12a

PII: S0145-2126(00)00081-3

doi: 10.1016/S0145-2126(00)00081-3

Leukemia Research
Volume 24, Issue 12 , Pages 1009-1011 , December 2000

Article Tools